The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells

In Ph-positive (Ph(+)) leukemia, the quiescent cell state is one of the reasons for resistance to the BCR-ABL-kinase inhibitor, imatinib. In order to examine the mechanisms of resistance due to quiescence and the effect of the mammalian target of rapamycin inhibitor, everolimus, for such a resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuwatsuka, Y, Minami, M, Minami, Y, Sugimoto, K, Hayakawa, F, Miyata, Y, Abe, A, Goff, D J, Kiyoi, H, Naoe, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255258/
https://www.ncbi.nlm.nih.gov/pubmed/22829152
http://dx.doi.org/10.1038/bcj.2011.16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255258/
https://www.ncbi.nlm.nih.gov/pubmed/22829152
http://dx.doi.org/10.1038/bcj.2011.16

Ejemplares similares